Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function

← catalyst calendar

NCT07751250 · readout ≤ 285 d

Sponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →.

Phase

Phase 1

Status

Not yet recruiting

Study type

Interventional

Design

Non randomized · None · Basic science

Enrollment

16estimated

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

Aug 2026

estimated

When the study began enrolling

Primary completion

May 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

May 2027

estimated

The whole study's end, after follow-up

First posted

2026-08-07

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-07

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Healthy Participants
Hepatic Impairment

Intervention

Drug: Casdatifan

Primary outcomes

what the primary-completion date above is the date OF

Area under the concentration time curve, from time 0 to the last observed non-zero concentration, of casdatifan in plasma (AUC0-t)

measured Up to 10 days post-dose

Area under the concentration time curve from time 0 extrapolated to infinity of casdatifan in plasma (AUC0-inf)

measured Up to 10 days post-dose

Maximum observed concentration of casdatifan in plasma (Cmax)

measured Up to 10 days post-dose

Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed